Linking assertions to evidence with the MicroPublications ontology WG evidence 2014-03-26

•Download as PPTX, PDF•

1 like•873 views

How can we link assertions to evidence in the scientific literature? Discussion about the MicroPublications ontology (http://purl.org/mp/ & see http://arxiv.org/abs/1305.3506 ) Presented to the WG Evidence Panel of the Addressing PDDI Evidence Gaps project https://sites.google.com/site/ddikrandir/home/wg-evidence-panel

Science Health & Medicine Education

Jodi Schneider
http://jodischneider.com/jodi.html
WG Evidence - Addressing PDDI Evidence Gaps
March 26, 2014

goal
Record relationships between assertions and evidence
Assertions:
“there (is/is not) an interaction between A & B”
“Enzyme E reduces clearance of drug D by 25%”
Evidence:
Scientific literature, drug product labeling, FDA guidance
documents

DIKB
Assertions (siocns:content)
“The aim of this study was to compare the pharmacokinetics
of diltiazem its major metabolites in healthy human
volunteers representing different CYP2D6 genotypes.”
Evidence type (dikbEvidence:Evidence_type)
dikbEvidence:EV_CT_PK_Genotype
supports (is swanco:citesAsSupportingEvidence of)
<http://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Assertions/9>
desacetyldiltiazem_substrate_of_cyp2d6

MicropublicationsModel the relationship between assertions and evidence
Features:
Designed for bioinformatics
Improves on previous models
Integrates annotation (Domeo)
Enhanced argumentative reasoning

Micropublications
Micropublications: a Semantic Model for Claims, Evidence, Arguments and Annotations in Biomedical Communications
Tim Clark, Paolo N. Ciccarese, Carole A. Goble
http://arxiv.org/abs/1305.3506

Micropublications: a Semantic Model for Claims,
Evidence, Arguments and Annotations in Biomedical
Communications
Tim Clark, Paolo N. Ciccarese, Carole A. Goble
http://arxiv.org/abs/1305.3506

Micropublications
as a new evidence model
Can micropublications be used in the next
version of the DIKB?
Micropublications: a Semantic Model for Claims,
Evidence, Arguments and Annotations in Biomedical
Communications
Tim Clark, Paolo N. Ciccarese, Carole A. Goble
http://arxiv.org/abs/1305.3506

Linking assertions to evidence with the MicroPublications ontology WG evidence 2014-03-26

What's hot

Disease Network is the science that has emerged to diagnose a disease from a network aspect specifically. Networks are the group that interconnect to each others similarly disease networks are the one that reveal concelled connection among apparently independent biomedical entities like physiologic process, signaling receptors, in addition to genetic code, also they prove to exists intitutive in addition to powerful way to learn/discover or diagnose a disease.Due to these networks, we can now consume the elderly drugs and its method to learn/discover the new drug accordingly.Example- Colchicine is used in gout but after repurposing it is also used in mediterranean fever. This is because there are many factors that affect the body during mediterranean fever and gout, we know that gout is a form of arthritis that causes pain in joints also mediterranean fever is the one which is accompanied by pain in joints, therefore colchicine is used as a repurposed drug again.In repurposing of medicines or drugs we first analyse the change in symptoms and identify the target organ and accorgingly we produce a drug that is compatible with pharmacokinetics of the body. As the availablity of transcriptomic,proteomic and metabolomic data sources are increasing day by day it helps in classification of disease .Also there are some networks reffered to as complex networks which can be called as collection of linked junctions/ nodes

NETWORK OF DISEASES AND ITS ENDOWMENT TOWARDS DISEASE

IJTRET-International Journal of Trendy Research in Engineering and Technology

In science, data visualization serves two primary purposes. The first is to explore data sets interactively and the second is to communicate discoveries. However, the requirements for visualizations employed in these activities are very different. Therefore, the software tools used for these purposes are typically disconnected, creating significant challenges for reproducibility and effective communication of discoveries in data-driven biomedical science. In this presentation, I will address how a new approach to creating data visualization tools can connect data analysts and other stakeholders inside and outside the scientific community. I will introduce and demonstrate the "Vistories" approach that was motivated by these question. Presented at the 5th Cancer Research UK Big Data Analytics Conference on Data Visualization.

Data Visualization in Biomedical Sciences: More than Meets the Eye

Nils Gehlenborg

Discussion of Dynamic Enhancement of Drug Product Labels at Data Integration ...

Richard Boyce, PhD

Wikipedia and Biomedical Research

Dahlgren Memorial Library

Overcoming obstacles to repurposing for neurodegenerative disease

Lona Vincent

Acquiring and representing drug-drug interaction knowledge and evidence, TRIA...

jodischneider

Joseph M. Young CV

Joseph Young

These are slides I used for a presentation to a group of graduate students about to undertake their field work for their capstone project in public health. The aim of the presentation was to provide guidance for topic selection, developing research questions, creating search strategies, conducting searches, and managing search results. The concepts and and methods are informed by standards for systematic review but are presented at a more general and less rigorous level.

Search Concepts, Methods, Resources, and Tools

John Pell

Patient Centered Care | Unit 8b Lecture

CMDLMS

Antibiotic Discovery Webinar

Lixin Liu

Roche_open_science_NIOO_KNAW_workshop_NL

Dominique Roche

Open Drug Discovery Teams Feature Overview

Alex Clark

MDC Connects Series 2021 | A Guide to Complex Medicines: Developing the assay...

Medicines Discovery Catapult

Badapple: promiscuity patterns from noisy evidence (poster)

Jeremy Yang

2009 09 Lod London

Jun Zhao

Brief update to W3C HCLS on representing and linking potential drug-drug inte...

Richard Boyce, PhD

Aries systems eemug 2021 manuscript eval services panel sci score v2_edits

Anita Bandrowski

Repeatability and Reproducibility in science

pramod41kumar

Scott Edmunds: GigaScience Datacite meeting Rapid Fire Talk

GigaScience, BGI Hong Kong

Complex Systems Biology Informed Data Analysis and Machine Learning

Dmitry Grapov

What's hot (20)

NETWORK OF DISEASES AND ITS ENDOWMENT TOWARDS DISEASE

Data Visualization in Biomedical Sciences: More than Meets the Eye

Discussion of Dynamic Enhancement of Drug Product Labels at Data Integration ...

Wikipedia and Biomedical Research

Overcoming obstacles to repurposing for neurodegenerative disease

Acquiring and representing drug-drug interaction knowledge and evidence, TRIA...

Joseph M. Young CV

Search Concepts, Methods, Resources, and Tools

Patient Centered Care | Unit 8b Lecture

Antibiotic Discovery Webinar

Roche_open_science_NIOO_KNAW_workshop_NL

Open Drug Discovery Teams Feature Overview

MDC Connects Series 2021 | A Guide to Complex Medicines: Developing the assay...

Badapple: promiscuity patterns from noisy evidence (poster)

2009 09 Lod London

Brief update to W3C HCLS on representing and linking potential drug-drug inte...

Aries systems eemug 2021 manuscript eval services panel sci score v2_edits

Repeatability and Reproducibility in science

Scott Edmunds: GigaScience Datacite meeting Rapid Fire Talk

Complex Systems Biology Informed Data Analysis and Machine Learning

Similar to Linking assertions to evidence with the MicroPublications ontology WG evidence 2014-03-26

Sunday (2) lipinski

plmiami

Sunday lipsinki

plmiami

Big data plays an important role in promoting emerging scientific and interdisciplinary research by enabling decision-making. However, in order to provide actionable insights relevant for the support of decision-making, several challenges for data management, analytics, and knowledge discovery need to be addressed. In this talk, we will describe a knowledge-driven approach capable to ingest Big data sources and integrate them into a knowledge graph that represents not only the meaning of the entities published by these data sources, but also that provides the basis for the discovery of unknown patterns and associations between these entities. The features of this knowledge-driven framework are shown in the context of the EU funded project iASiS (http://project-iasis.eu/) , where it is used to pave the way for personalized diagnosis and treatments

Synthesizing Big Data into Actionable Knowledge

Maria-Esther Vidal

RESEARCH ARTICLE Association between 25(OH)D Level, Ultraviolet Exposure, Geographical Location, and Inflammatory Bowel Disease Activity: A Systematic Review and Meta-Analysis Chao Lu, Jun Yang, Weilai Yu, Dejian Li, Zun Xiang, Yiming Lin, Chaohui Yu* Department of Gastroenterology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China * [email protected] Abstract Background There is no consensus on the vitamin D levels and inflammatory bowel disease (IBD). Aim To conduct a systematic review and meta-analysis to analyze the relationship between IBD and 25(OH)D, sun exposure, and latitude, and to determine whether vitamin D deficiency affects the severity of IBD. Methods We searched the PubMed, EBSCO, and ClinicalTrials.gov databases to identify all studies that assessed the association between 25(OH)D, sun exposure, latitude, and IBD through November 1, 2014, without language restrictions. Studies that compared 25(OH)D levels between IBD patients and controls were selected for inclusion in the meta-analysis. We cal- culated pooled standardized mean differences (SMDs) and odds ratios (ORs). Results Thirteen case-control studies investigating CD and 25(OH)D levels were included, and eight studies part of above studies also investigated the relationship between UC and 25(OH)D. Both CD patients (SMD: 0.26 nmol/L, 95% confidence interval [CI]: 0.09–0.42 nmol/L) and UC patients (SMD: 0.5 nmol/L, 95% CI: 0.15–0.85 nmol/L) had lower levels of 25(OH)D than controls. In addition, CD patients and UC patients were 1.95 times (OR, 1.95; 95% CI, 1.48– 2.57) and 2.02 times (OR, 2.02; 95% CI, 1.13–3.60) more likely to be 25(OH)D deficient than controls. We also included 10 studies investigating the relationship between CD activity and vitamin D. Results showed that patients with active CD (CD Activity Index�150) were more likely to have low vitamin D levels. In addition, whether low sun exposure and high latitude were related to a high morbidity of CD need to be provided more evidence. PLOS ONE | DOI:10.1371/journal.pone.0132036 July 14, 2015 1 / 16 OPEN ACCESS Citation: Lu C, Yang J, Yu W, Li D, Xiang Z, Lin Y, et al. (2015) Association between 25(OH)D Level, Ultraviolet Exposure, Geographical Location, and Inflammatory Bowel Disease Activity: A Systematic Review and Meta-Analysis. PLoS ONE 10(7): e0132036. doi:10.1371/journal.pone.0132036 Editor: John Green, University Hospital Llandough, UNITED KINGDOM Received: March 25, 2015 Accepted: June 9, 2015 Published: July 14, 2015 Copyright: © 2015 Lu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: All relevant data are within the paper. Funding: The authors have no support or funding to report. Competing Interests ...

RESEARCH ARTICLEAssociation between 25(OH)D Level,Ultrav.docx

debishakespeare

In this review report we like to focus on the new challenges in methodology of modern biology be used in medical science. Today human health is a primary issue to cure disease, undoubtedly the answer to this is bioinformatics or (In-silco) tools has change the concept of treating patients to understand the need of genomic medicine in use. Those with new modes of action in clinical treatment, is a major health concern in medical science. On global prospective scientific role in constructing new ideas to remediate health care to treat disease exciting in nature is challenging task. So awareness needs to accelerate store clinical datasets for scientific represents to design genomic drugs. This new outline will drive the medical to discover public data and create a cognitive approach to use technology cheaper at cost effective mode.

Bioinformatics in the Clinical Pipeline: Contribution in Genomic Medicine

iosrjce

Definiciones sepsis. pccm 2005

miranada cabanillas jhoanatan

Vit d

evacalvo

Probioticos x antibóticos

lactivos

Open PHACTS webinar June 2016 - Data2Discovery

open_phacts

Acquiring and representing drug-drug interaction knowledge and evidence, Litm...

jodischneider

Synergistic actions of vitamin D3 and vitamin K2

Kevin KF Ng

11JAN17 Lindsay Jordan Resume

Lindsay Wurst

Open data, compound repurposing, and rare diseases -- Point Loma Nazarene Uni...

Andrew Su

Background: Vitamin D is crucial for a wide variety of organ systems; nevertheless, evidence has demonstrated that vitamin D deficiency may place subjects at risk for not only low mineral bone density /osteoporosis and osteopenia but also infectious and chronic inflammatory diseases Vitamin D also has anti-inflammatory effects by suppressing pro-inflammatory cytokines through its effect on bone and mineral metabolism, innate immunity and several VDR gene polymorphisms, vitamin D has been reported to be associated with periodontal disease. Objectives: To assess anti-inflammatory effect of vitamin D3, when administered as monotherapy in generalised chronic periodontitis. Methods: This study comprises of 56 patients of generalised chronic periodontitis who were screened for their serum vitamin D3 levels. Out of which 30 patients who were vitamin D3 deficient (<20ng /><0.002)><0.000). Conclusion: Vitamin D deficiency may place subjects at risk for not only low bone mineral density/osteoporosis and osteopenia, but also infectious and chronic inflammatory diseases like periodontitis.

Vitamin D And Chronic Periodontitis – A Randomised Double Blinded Placebo Con...

inventionjournals

Vitamin D And Chronic Periodontitis – A Randomised Double Blinded Placebo Con...

inventionjournals

Vitamin D

Naresh Pokhrel

#DIACMC17 Assigned title for the talk by the organizers:“The need of conducting clinical study for assuring safety and efficacy, as well as a lack of immunogenicity for generic NBCDs” SUMMARY Integrated analytical, product and process development to reduce uncertainty in ‘pharmaceutical equivalence’ is the foundation on which confidence in generic drugs rests Need to leverage the context: RLD “Prescribe-ability” and lot-lot “Switchability” is acceptable The “sameness” mindset (as opposed to an “equivalence” mindset) poses challenges to evidence ‘synthesis” (not “piece meal” check the box ) in ANDA submissions Integrated evidence must a priori account for posed/anticipated “legal challenges” intrinsic to the US system Clinical assessment of Therapeutic Equivalence of generic product intended (i.e., designed) to be equivalent to RLD should only be needed in rare circumstances When there is a need to provide assurance to non-scientists stakeholders Currently the FDA’s GADUFA Research and efforts by many in the sector are predominantly focused on developing a “test of bioequivalence” For most complex products such a test, in and of itself, may be insufficient to ensure therapeutic equivalence over generic product life-cycle

Generic non-biological complex drugs DIA CMC Workshop 2017

Ajaz Hussain

Pine Biotech - a company that merges big -omics data analysis with clinical care and precision applications for Real World Evidence: research & development of new targets and therapeutics, stratified clinical trials, and development of biomarkers for early detection and companion diagnostics. We want to improve patient outcomes and provide tools for researchers and clinicians to have an impact on healthcare.

Pine Biotech

Elia Brodsky

Inadequate representation of evidence and knowledge about potential drug-drug interactions is a major factor underlying disagreements among sources of drug information that are used by clinicians. In this paper we describe the initial steps toward developing a foundational domain representation that allows tracing the evidence underlying potential drug-drug interaction knowledge. The new representation includes biological and biomedical entities represented in existing ontologies and terminologies to foster integration of data from relevant fields such as physiology, anatomy, and laboratory sciences.

Towards a foundational representation of potential drug-drug interaction know...

Mathias Brochhausen

Abstract Pharos (https://pharos.nih.gov/) is an integrated web-based informatics platform for the analysis of data aggregated by the Illuminating the Druggable Genome (IDG) Knowledge Management Center, an NIH Common Fund initiative. The current version of Pharos (as of October 2019) spans 20,244 proteins in the human proteome, 19,880 disease and phenotype associations, and 226,829 ChEMBL compounds. This resource not only collates and analyzes data from over 60 high-quality resources to generate these types, but also uses text indexing to find less apparent connections between targets, and has recently begun to collaborate with institutions that generate data and resources. Proteins are ranked according to a knowledge-based classification system, which can help researchers to identify less studied “dark” targets that could be potentially further illuminated. This is an important process for both drug discovery and target validation, as more knowledge can accelerate target identification, and previously understudied proteins can serve as novel targets in drug discovery. In this webinar, Dr. Tudor Oprea will introduce how to use Pharos to find targets of interest for drug discovery. The top 3 key questions that Pharos can answer: 1. What are the novel drug targets that may play a role in a specific disease? 2. What are the diseases that are related directly or indirectly to a drug target? 3. Find researchers that are related directly or indirectly to a drug target. Presenter: Tudor Oprea, MD, PhD, Professor of Medicine, Chief of Translational Informatics Division & Internal Medicine, University of New Mexico dkNET Webinar Information: https://dknet.org/about/webinar

dkNET Webinar: Illuminating The Druggable Genome With Pharos 10/23/2020

dkNET

More from jodischneider

Continued Citation of Bad Science and What We Can Do About It Even papers that falsify data continue to be cited. I describe network and text analysis for studying how authors continue to cite bad science: articles retracted from the literature due to serious flaws or errors. I will present an in-depth case study of a human trial cited for over 10 years after it was retracted for falsifying data. Then, I will describe how the team scaled up to study a data set of 7000 retracted papers and hundreds of thousands of citations. Finally, I will discuss an ongoing Sloan-funded stakeholder consultation that is bringing editors, publishers, librarians, researchers, and research integrity experts together to address this problem. BiographyJodi Schneider is Assistant Professor at the School of Information Sciences, University of Illinois at Urbana-Champaign where she runs the Information Quality Lab. She studies the science of science through the lens of arguments, evidence, and persuasion with a special interest in controversies in science. Her recent work has focused on topics such as systematic review automation, semantic publication, and the citation of retracted papers. Interdisciplinarity (PhD in Informatics, MS Library & Information Science, MA Mathematics; BA Great Books/liberal arts) is a fundamental principle of her work. She has held research positions across the U.S. as well as in Ireland, England, France, and Chile. She leads the Alfred P. Sloan-funded project, Reducing the Inadvertent Spread of Retracted Science: Shaping a Research and Implementation Agenda. With Aaron Cohen and Neil Smalheiser she is working on the NIH R01 "Text Mining Pipeline to Accelerate Systematic Reviews in Evidence-Based Medicine". Talk with her about scoping reviews and about citation-based methods for updating systematic reviews! Tuesday, April 20th, 2021 Noon-1PM Eastern GWU - CNHS Informatics Seminar

Continued citation of bad science and what we can do about it--2021-04-20

jodischneider

Title: Continued Citation of Bad Science and What We Can Do About It Abstract: Even papers that falsify data continue to be cited. I describe network and text analysis for studying how authors continue to cite bad science: articles retracted from the literature due to serious flaws or errors. Jodi will present an in-depth case study of a human trial cited for over 10 years after it was retracted for falsifying data. Then, will describe how the team scaled up to study a data set of 7000 retracted papers and hundreds of thousands of citations. Finally, Jodi will discuss an ongoing Sloan-funded stakeholder consultation that is bringing editors, publishers, librarians, researchers, and research integrity experts together to address this problem.

Continued citation of bad science and what we can do about it--2021-02-19

jodischneider

Presentation for the Bibliometrics & Research Assessment Symposium 2020 (bibSymp20) https://www.nihlibrary.nih.gov/services/bibliometrics/bibSymp20 October 9, 2020 Retraction is intended to remove articles from the citable literature. However, a series of studies from over 30 years, from 1990 through 2020, have found that many retracted papers continue to be cited, and cited positively, even following misconduct-related retractions. For instance, a fraudulent clinical trial report retracted in 2008 continues to receive citations in 2020, and 96% of post-retraction citations do not mention its citation - perhaps because its retraction not marked on the publisher website and its retraction notice cannot be readily retrieved from 7 out of 8 databases (8 out of 9 database records) we tested. This talk draws an ongoing systematic mapping study of research about retraction and our own research projects to summarize what is known about post-retraction citation in biomedicine. We outline practical steps that authors and reviewers can take to avoid being caught out by poorly marked retracted papers. 20 minutes including Q&A

The problems of post retraction citation - and mitigation strategies that wor...

jodischneider

JCDL2020 full paper. Abstract: Scientific digital libraries speed dissemination of scientific publications, but also the propagation of invalid or unreliable knowledge. Although many papers with known validity problems are highly cited, no auditing process is currently available to determine whether a citing paper’s findings fundamentally depend on invalid or unreliable knowledge. To address this, we introduce a new framework, the keystone framework, designed to identify when and how citing unreliable findings impacts a paper, using argumentation theory and citation context analysis. Through two pilot case studies, we demonstrate how the keystone framework can be applied to knowledge maintenance tasks for digital libraries, including addressing citations of a non-reproducible paper and identifying statements most needing validation in a high-impact paper. We identify roles for librarians, database maintainers, knowledge base curators, and research software engineers in applying the framework to scientific digital libraries. doi:10.1145/3383583.3398514 Preprint: http://jodischneider.com/pubs/jcdl2020.pdf

Towards knowledge maintenance in scientific digital libraries with the keysto...

jodischneider

Keynote talk 2020-08-01 for the JCDL Workshop on Conceptual Models: https://sig-cm.github.io/news/JCDL-2020-CFP/ Discussion points: * Methods are a key part of the Knowledge Organizing Structure for Evidence-Based Medicine. * Methods relate to how we GENERATE evidence. * Different methods generate evidence of different kinds and strength. * I believe Methods can be useful in mining claims and arguments from papers: methods AUTHORIZE claims. * More specialized hierarchies of evidence can be found in medicine * Various groups are complicating the “evidence pyramid” hierarchy of evidence.

Methods Pyramids as an Organizing Structure for Evidence-Based Medicine--SIGC...

jodischneider

Annotation examples. This is an overview of some of the software I have used for annotation (and a few extra features some of this software has.) This was presented in the SwissUniversities Doctoral Programme, Language & Cognition, in the Module: Linguistic and corpus perspectives on argumentative discourse. Screenshots are given of GATE, UAM Corpus Tool, Excel, BRAT, EPPI Reviewer, and a custom tool. In most cases there are references to one of my papers for further details. I briefly describe a typical annotation process: Find text of interest Find phenomena of interest Draft an annotation manual Iteratively test annotation & revise manual Find questionable annotations, check disagreements. Revise the manual. Iterate. Annotate

Annotation examples--Fribourg--2019-09-03

jodischneider

An introduction to argumentation mining for PhD students. This was presented in the SwissUniversities Doctoral Programme, Language & Cognition, in the Module: Linguistic and corpus perspectives on argumentative discourse. The presentation largely follows Chapters 1-4 and Chapter 10 of my book, Argumentation Mining, co-authored with Manfred Stede in the Synthesis Lectures on Human Language Technologies from Morgan & Claypool: https://doi.org/10.2200/S00883ED1V01Y201811HLT040 Topics: My book w/computational linguist Manfred Stede: Argumentation Mining What is argumentation? Argumentation mining: a first look Argumentative language Challenges for argumentation mining Argumentation structures Corpus annotation Why study argumentation mining?

Argumentation mining--an introduction for linguists--Fribourg--2019-09-02

jodischneider

Talk at the 3rd European Conference on Argumentation ABSTRACT: Specialized fields may at any time invent new inference rules—that is, new warrants—to improve on their stock of resources for drawing and defending conclusions. Yet disagreement over the acceptability of an invented warrant can always be re-opened. Randomized Clinical Trial is widely regarded as the gold standard for making inferences about causal relationships between medical treatments and patient outcomes. Once controversial, RCT achieved broad acceptance within the field as a result of warrant-establishing arguments circulating in the medical literature starting in the 1950s. And RCT has accumulated a very impressive track record of generating new conclusions that withstand critical scrutiny. Here we look at two emerging innovations whose purpose is to support reasoning about health, offering ways to generate different classes of conclusions. These innovations could be seen as complementary to RCTs, but for both there are also hints of challenge to the enormous prestige of RCTs. We see this most particularly in the gap that has developed between the RCT-generated fact base and the decisions doctors and health policy officials have to make about treatments for patients. We’ve mentioned before that specialized inference methods that become stabilized within an expert community can meet unexpected challenges when they become components of reasoning by other communities. The two innovations considered here each allow us to explore the tensions that arise from the contrasting perspectives of scientists, clinicians, and patients.

Beyond Randomized Clinical Trials: emerging innovations in reasoning about he...

jodischneider

Publishers are caretakers of science. Part of that work is maintaining the integrity of scientific literature. Science builds directly upon past work, so we need to be sure that we are building upon a solid foundation and not faulty research. Publishers need to take an active role in monitoring and tracking faulty, retracted research and its influence. I'm asking publishers to (1) clearly mark retracted papers; (2) alert authors who have already cited a retracted paper; and (3) before publishing an article, check its bibliography for retracted papers. Retracted papers should be clearly marked everywhere they appear, but today that is not the case. Publishers can also use the CrossRef CrossMark service, which lets readers check for article updates (such as retraction) from a little red ribbon at the top of an article. Checking for citations to retracted articles, and limiting future citations, can help science self-correct by shoring up its foundations.

Problem-citations--CrossrefLive18--2018-11-13

jodischneider

The structure of citation networks provides evidence about how scientific information is diffused. Problematic citation patterns include the selective citation of positive findings, citation bias, as well as the continued citation of retracted literature (i.e. literature formally withdrawn due to error, fraud, or ethical problems). For instance, there is some evidence that positive results tend to receive more citations. The public domain licensing of the Open Citations Corpus makes it possible, in principle, to estimate the likelihood that any network of research papers suffers from problematic citation. To-date, problematic citation been documented ad-hoc, in several striking studies. In Alzheimer's disease research, biased citation, ignoring critical findings, was used to support successful U.S. NIH grant proposals (Greenberg 2009). Mistranslation of obesity research has been used to justify exertion game research (Marshall & Linehan 2017). Citation of fraudulent research about Chronic Obstructive Pulmonary Disease continued after its retraction (Fulton et al. 2015). The data resulting from such studies is of great use to my lab in replicating and determining how to generalize the detection of problematic citation patterns. Previously, the detection of problematic citation patterns has been a side effect of astute researchers, noticing suspicious findings while conducting systematic literature reviews. This talk will describe work-in-progress in my lab detecting problematic citation patterns using natural language processing, combined with network analysis on the Open Citations Corpus.

Problematic citations--Workshop-on-Open-Citations--2018-09-03

jodischneider

Presentation: Jodi Schneider and Novejot Sandhu, “Modeling Alzheimer’s Disease Reseach Claims, Evidence, and Arguments from a Biology Research Paper.” 9th International Conference on Argumentation, International Society for the Society of Argumentation, Amsterdam, Netherlands, July 5, 2018 Abstract: Argument visualization may help make research papers easier to understand, which could both speed quality assessment within a discipline and help build interdisciplinary knowledge networks. This paper presents a case study of the arguments in a single high-profile paper on Alzheimer's disease research. Within this one paper, we analyze and hand-annotate the main claim, which is supported by 4 subclaims, in turn supported by data, methods, and materials. We also investigate how the paper imports and uses knowledge claims from other research papers. We create a specialized argument-based knowledge representation called a micropublication. In future work, we will investigate automatic argumentation mining for experimental biology research papers. Our long-term vision is to create literature-scale claim-argument networks that help more quickly use new knowledge about human health.

Modeling Alzheimer’s Disease research claims, evidence, and arguments from a ...

jodischneider

Presentation: Jodi Schneider and Sally Jackson, “Innovations in Reasoning About Health: The Case of the Randomized Clinical Trial.” 9th International Conference on Argumentation, International Society for the Society of Argumentation, Amsterdam, Netherlands, July 5, 2018 Abstract: Field-dependence in argumentation comes about through forms of inference invented by specialized fields. In recent work we introduced the concept of a "warranting device": (1) an inference license (2) invented for a specialized argumentative purpose and (3) backed by institutional, procedural, and material assurances of the dependability of conclusions generated by the device. Once established, fields employ such devices across many situations without further defense, even as the devices develop in response to newly-noticed problems. Many new warranting devices have appeared over the past century to solve problems in reasoning about health and medicine, replacing and obsolescing earlier forms of medical reasoning. One such device is the Randomized Controlled Trial. This case study traces its historical evolution and discusses some current movements toward competing device types.

Innovations in reasoning about health: the case of the Randomized Clinical Tr...

jodischneider

Viewing universities as landscapes of scholarship, VIVO keynote, 2017-08-04

jodischneider

European Conference on Argumentation talk Jodi Schneider, Graciela Rosemblat, Shabnam Tafreshi and Halil Kilicoglu “Rhetorical moves and audience considerations in the discussion sections of Randomized Controlled Trials of health interventions” [Conference Panel Presentation], 2nd European Conference on Argumentation: Argumentation and Inference, Fribourg, Switzerland, June 20-23 1 of 3 talks in Jodi Schneider and Sally Jackson, organizers, “Innovations in Reasoning and Arguing about Health ”[Conference Panel], 2nd European Conference on Argumentation: Argumentation and Inference, Fribourg, Switzerland, June 20-23.

Rhetorical moves and audience considerations in the discussion sections of ra...

jodischneider

Citation practices and the construction of scientific fact--ECA-facts-preconf...

jodischneider

What WikiCite can learn from biomedical citation networks--Wikicite2017--2017...

jodischneider

Medication safety as a use case for argumentation mining We present a use case for argumentation mining, from biomedical informatics, specifically from medication safety. Tens of thousands of preventable medical errors occur in the U.S. each year, due to limitations in the information available to clinicians. Current knowledge sources about potential drug-drug interactions (PDDIs) often fail to provide essential management recommendations and differ significantly in their coverage, accuracy, and agreement. The Drug Interaction Knowledge Base Project (Boyce, 2006-present; dikb.org) is addressing this problem. Our current work is using knowledge representations and human annotation in order to represent clinically-relevant claims and evidence. Our data model incorporates an existing argumentation-focused ontology, the Micropublications Ontology. Further, to describe more specific information, such as the types of studies that allow inference of a particular type of claim, we are developing an evidence-focused ontology called DIDEO--Drug-drug Interaction and Drug-drug Interaction Evidence Ontology. On the curation side, we will describe how our research team is hand-extracting knowledge claims and evidence from the primary research literature, case reports, and FDA-approved drug labels for 65 drugs. We think that medication safety could be an important domain for applying automatic argumentation mining in the future. In discussions at Dagstuhl, we would like to investigate how current argumentation mining techniques might be used to scale up this work. We can also discuss possible implications for representing evidence from other biomedical domains. Talk for Dagstuhl Seminar 16161: Natural Language Argumentation: Mining, Processing, and Reasoning over Textual Arguments http://www.dagstuhl.de/en/program/calendar/semhp/?semnr=16161

Medication safety as a use case for argumentation mining, Dagstuhl seminar 16...

jodischneider

A talk for the Moore Institute for Humanities - People and documents are of enduring interest. Documents may be generated by individuals, collective groups, and administrations, on any number of topics. We are particularly interested in the relationships between people and documents. The most important relationships are creation (authors, illustrators, translators, ...), usage (e.g. association copies), and topic-of (e.g. people may be the subjects of biographies). In this lecture, we will talk about several approaches for modeling, or representing, people and documents. We pay particular attention to computer-based approaches to organization, and to organizing information for websites. We will talk briefly about TEI and XML, and the focus on my area of research expertise: modeling "linked data", a widely adopted approach for interlinking data. Adopted by the UK and US governments and search engines such as Google and Yahoo!, linked data has also been widely used in the digital humanities and by libraries, archives, and museums. It consists in naming objects of interest (be they authors, documents, or whatnot) and using standard data formats to enable interlinking.

Persons, documents, models: organising and structuring information for the We...

jodischneider

Synthesizing knowledge from disagreement -- Manchester -- 2015-05-06

jodischneider

Synthesizing knowledge from disagreement -cwi-2015-04-23

jodischneider

More from jodischneider (20)